Open AccessIncidental breast lesion detected by technetium-99m sestamibi scintigraphy in a patient with primary hyperparathyroidism
Author(s) -
Sakditad Saowapa,
Wichana Chamroonrat,
Ronnarat Suvikapakornkul,
Chutintorn Sriphrapradang
Publication year - 2020
Publication title -
world journal of nuclear medicine
Language(s) - English
Resource type - Journals
eISSN - 1607-3312
pISSN - 1450-1147
DOI - 10.4103/wjnm.wjnm_5_19
Subject(s) - medicine , primary hyperparathyroidism , scintigraphy , technetium (99mtc) sestamibi , hyperparathyroidism , technetium tc 99m sestamibi , lesion , radiology , adenoma , breast imaging , thyroid , parathyroid adenoma , technetium , parathyroid neoplasm , nuclear medicine , lung , mammography , pathology , breast cancer , cancer
Nuclear scintigraphy is functional imaging and can be combined with anatomical imaging to improve diagnostic yield. Detection of parathyroid lesion by technetium-99m methoxyisobutylisonitrile (Tc-99m MIBI) can facilitate an appropriate operative approach in a patients with primary hyperparathyroidism. Tc-99m MIBI is concentrated in highly cellular or metabolically active tissues, which have abundant mitochondria. False-positive scintigraphic findings could be from head-and-neck carcinomas, thyroid neoplasm, and multinodular goiter. In addition, multiple organs outside of the neck region, such as lung and breast, can take up the Tc-99m MIBI. Herein, we report the occurrence of abnormal focal uptake in the breast region during the preoperative localization of parathyroid adenoma and later discovered breast carcinoma.